Axon Therapies Announces Positive Early Clinical Data from REBALANCE-HF Randomized Clinical Trial

Late-breaking results presented at the European Society of Cardiology’s Heart Failure Association annual conference and simultaneously published online in the European Journal of Heart Failure

Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced positive early results from a roll-in cohort for their feasibility IDE trial, REBALANCE-HF. The study is evaluating a novel frontline therapy called Splanchnic Ablation for Volume Management (SAVM) that aims to rebalance volume distribution in heart failure patients with preserved ejection fraction (HFpEF).

The results support safety and efficacy of the SAVM procedure and signaled clinical improvements in key data including pulmonary capillary wedge pressure (PCWP) with exercise and patient quality of life metrics. Data was presented at the European Society of Cardiology’s Heart Failure Association 2022 annual conference in Madrid, Spain and simultaneously published online in the European Journal of Heart Failure.

“It is very promising to see the positive early dataset and improvement in key clinical outcomes. HFpEF patients have few treatment options today, and SAVM offers a minimally invasive, implant-free procedure designed to treat a root cause of their symptoms and hopefully slow down or stop disease progression – it has the potential to be a very exciting approach,” commented Marat Fudim, MD, Advanced Heart Failure Specialist at Duke University Medical Center. “I’m eager to see the longer-term results and patient outcomes from the study as they become available.”

The REBALANCE-HF study is a prospective, multi-center, randomized, sham controlled, double-blinded study enrolling 80 patients at up to 20 U.S. sites and is designed to assess the safety and efficacy of the SAVM procedure. The trial included a cohort of 18 single-arm, open-label roll-in patients for interim analysis that provided early data on the SAVM procedure using the Axon Ablation Catheter. While the findings require additional confirmation, early results are very promising. The therapy had a solid safety profile—all patients were successfully treated and three non-serious device-related adverse events were reported (heart failure decompensation requiring an ER visit, transient hypertension during the procedure, and back pain following the procedure). Patients showed improvement in PCWP with exercise as well as improvements in functional capacity, symptoms, and overall health status.

Key Results
• Significant reduction in PCWP at 20 watts and peak exercise at 1-month (p=0.007 and p=0.013, respectively)
• 33% of patients experienced improvement of at least one New York Heart Association (NYHA) class compared to baseline at 1-month (p<0.01)
• Significant improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) (22.1 pts at 1-month, p <0.01; 18.3 pts at 3-months, p<0.01)

Sanjiv Shah, MD, who is the National Principal Investigator of the REBALANCE-HF trial, stated, “The SAVM procedure offers a novel approach to potentially improving outcomes in patients suffering from heart failure by reducing sympathetic nerve activity to restore volume balance within the circulation. The early data from the REBALANCE-HF trial, demonstrates the potential promise and importance of managing volume shifts in this underserved patient population.” Dr. Shah is Director of Research for the Bluhm Cardiovascular Institute at Northwestern University Feinberg School of Medicine in Chicago, Illinois.

“The data for this first cohort of patients is very encouraging. We anticipate completing enrollment in REBALANCE- HF later this year and sharing the full results next year,” stated Chad Hoskins, CEO of Axon Therapies. “The data builds on the results of our pilot studies, which demonstrated a durable effect of SAVM at 1 year. We’re grateful for the work of our investigators, and we look forward to the culmination of these efforts in a pivotal trial beginning in 2023.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“It’s exciting to be one of the first two hospitals in Europe to use Stryker’s Mixed Reality Guidance System,” said Professor Berhouet. “I am also pleased to be leading a pilot study to investigate the safety and effectiveness of this new technology, alongside three other centres in France.”
The KnowU incorporates the sensor that the Company plans to submit to the FDA for clearance. This proprietary sensor has been tested and proven stable and accurate in the lab setting. It was included in the Company’s prototype to validate stability outside of the lab, and is now miniaturized and wearable.
The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy